The Health Resources and Services Administration today delayed to May 22 the effective date of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers, and invited comments on whether a delay to Oct. 1 would be more appropriate. The rule was set to take effect March 21 following an earlier two-week delay. “[The Department of Health and Human Services] believes that the delay of the effective date is necessary to consider questions of fact, law and policy raised in the rule, consistent with the ‘Regulatory Freeze Pending Review’ memorandum,” the notice states. “In addition, HHS believes that the delay of the effective date is necessary to provide regulated entities sufficient time to implement the requirements of the rule.” HRSA will accept comments through April 17.

Related News Articles

Headline
Eleven organizations representing health care providers, including the AHA, April 29 urged the Centers for Medicare & Medicaid Services not to hold…
Headline
The Department of Health and Human Services April 18 finalized its rule to establish a 340B Administrative Dispute Resolution process as required under the…
Headline
Rep. Brett Guthrie, R-Ky., today addressed attendees of AHA’s 2024 Annual Membership Meeting and touched on many of the biggest issues in health care:…
Headline
Sen. John Thune, R-S.D., April 16 updated AHA members on progress to extend telehealth waivers, offering hope that a solution will arise in end-of-year…
Headline
The Change Healthcare cyberattack was a significant event that caught many off guard, said the Centers for Medicare & Medicaid Services Administrator…
Headline
The voluntary Episode Quality Improvement Program for specialist physicians saved Medicare $20 million in its first year, the Maryland Health Services Cost…